Search

Your search keyword '"Alazawi, William"' showing total 269 results

Search Constraints

Start Over You searched for: Author "Alazawi, William" Remove constraint Author: "Alazawi, William"
269 results on '"Alazawi, William"'

Search Results

1. Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice

3. Measuring NAFLD models of care

4. National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022

5. A global research priority agenda to advance public health responses to fatty liver disease

6. WED-275 Understanding barriers to adoption of clinical guidelines for metabolic dysfunction-associated steatotic liver disease among hepatologists in Europe

7. THU-236-YI Oxysterol treatment causes indirect stellate cell activation: a potential mechanism linking steroid metabolising enzyme dysregulation with fibrosis

8. WED-248 A four-country modelling study on doubling MASH diagnostic rates by 2027

9. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group

12. Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study

16. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke : findings from matched cohort study of 18 million European adults

17. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

18. National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022

19. Improving prevention strategies for cardiometabolic disease

20. A global action agenda for turning the tide on fatty liver disease.

22. Update on Treatment for Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis.

26. Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)

30. Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review

36. A global research priority agenda to advance public health responses to fatty liver disease

37. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts

39. Factors associated with HCC stage at presentation and survival in an ethnically diverse UK population

49. The growing prevalence of nonalcoholic fatty liver disease (NAFLD), determined by fatty liver index, amongst young adults in the United States. A 20-year experience

Catalog

Books, media, physical & digital resources